Conference Coverage

ASH 2013: Live Coverage

Novel STAT5 Targets FasL in AML

Experts discuss miR-590, a novel STAT5 oncogenic miRNA that targets FasL in AML.

AE Reporting Sensitivity Relatively Low in Cooperative Group Trials

The current system of AE reporting has modest sensitivity and a demonstrable false positive rate in cooperative group trials.

Telomere Length Associated with Women's Cognition after HCT

Telomere length may be prognostic of cognitive impairment in women after HCT.

ABT-199 Shows Activity in High-Risk Relapsed/Refractory CLL

ABT-199 (GDC-0199) demonstrated antitumor activity in patients with high-risk relapsed/refractory CLL and SLL.

Biomarkers, AlloHSCT Predict Post-AML Relapse Prognosis

Cytogenetic and molecular abnormalities may also be prognostic of post-relapse prognosis.

Combo Ofatumumab/Chlorambucil Improved PFS in CLL with Comorbidities

Ofatumumab plus chlorambucil prolongs PFS in older patients with CLL and comorbidities.

Long-term Rituximab Maintenance Doubled PFS in Follicular Lymphoma

Long-term rituximab maintenance prolongs PFS in follicular lymphoma.

New Assay Paves Way for 'Personalized' Therapy in AML

New Assay Paves Way for 'Personalized' Therapy in AML

High-throughput sensitivity assay may make "personalized" therapy possible in relapsed or refractory AML.

RiBVD Benefits Elderly with Untreated Mantle Cell Lymphoma

RiBVD regimen appears effective in elderly patients with untreated mantle cell lymphoma.

Crizotinib Yields High Response Rates in ALK-positive Lymphoma

High response rates to crizotinib were seen in advanced, chemoresistant ALK-positive lymphoma.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs